Cost-Effectiveness of Integrated Care for Children with Chronic Conditions

By Melike Belenli Gümüş

October 1, 2024

Introduction

Chronic conditions are a growing burden in childhood, affecting 1.7 million children and young people (CYP) in England as of 2018. The UK struggles with chronic disease management, having one of the highest asthma mortality rates in Europe. Inadequate asthma care standards contribute to 46% of these deaths. Poor chronic disease management leads to higher healthcare costs and reduced health-related quality of life (HRQoL) in childhood, with long-term consequences for families and society. Furthermore, children with chronic conditions face worse academic performance. The cost to society for caring for preschool children following hospital attendance for asthma or wheeze is estimated at £14.53 million. Of this amount, 76% is borne by the National Health Service (NHS). Therefore, evaluating the cost-effectiveness of integrated care for children is crucial to address these challenges.

Integrated Care as a Solution

Redesigning paediatric healthcare to manage chronic conditions aligns with the NHS Long-Term Plan and policies among high-income countries. Integrated care, which connects primary, community, and specialised services, is proposed to improve chronic disease management. Evidence suggests integrated care may enhance HRQoL, but results on healthcare quality, costs, and cost-effectiveness are mixed. Limitations in current studies highlight the need for further research on integrated care systems for children.

The Children and Young People’s Health Partnership Model

The Children and Young People’s Health Partnership (CYPHP) Evelina London model aims to provide coordinated, biopsychosocial care in primary and community settings for CYP with at least one tracer condition (asthma, eczema, and constipation). Between 2018 and 2021, general practices in Southwark and Lambeth were grouped into clusters and randomised to CYPHP (intervention) or enhanced usual care (EUC, control). The CYPHP practices included local child health clinics, specialist nurse-led services, population health management, specialist team training, and multidisciplinary team case planning, in addition to EUC services.

Figure 1. Total cost components for intervention and EUC.

The CYPHP trial involved 97,970 children, including 1,731 participants with chronic conditions. The study used cost-effectiveness, cost-utility, and cost-benefit analyses to evaluate the intervention. Researchers conducted these analyses from both the NHS/Personal Social Service (PSS) and societal perspectives. The trial aimed to capture the diverse effects of CYPHP on health outcomes and costs.

Cost-Effectiveness of Integrated Care

A recent study evaluated the cost-effectiveness of CYPHP compared to EUC for children with severe chronic conditions from both NHS/PSS and societal perspectives, at 6 and 12 months. At the 6-month mark, CYPHP was not found to be cost-effective under both perspectives. Although positive trends began to emerge at 12 months, incremental cost-effectiveness ratio (ICER) under NHS/PSS perspective was as high as £45,586 per quality-adjusted life year (QALY). This value indicates that while the intervention becomes more cost-effective over time, it remains relatively expensive per unit of effectiveness gained.

Furthermore, from a societal perspective—which encompasses the effects on patients, families, schools, and time lost from school and work—CYPHP demonstrated trends towards cost-effectiveness, with an ICER of £22,966/QALY. Also, as shown in Figure 2, the probability of being cost-effective under the societal perspective ranged from 0.4 to 0.6 for willingness-to-pay (WTP) thresholds of £20,000/QALY and £30,000/QALY, respectively. The cost-benefit analysis indicated a positive net monetary benefit of CYPHP at 12 months.

Figure 2. Probabilistic results of the cost-utility analysis, societal perspective at 12 months.

Conclusion

In conclusion, CYPHP was not cost-effective compared to EUC at 6-month follow-up. However, at 12 months, it shows trends towards cost-effectiveness, particularly under the societal perspective and among children with severe chronic conditions. Further research is needed to explore the long-term effects of CYPHP as it becomes more embedded in paediatric healthcare delivery. The positive change in findings between 6 and 12 months suggests that CYPHP may have a beneficial long-term impact on health outcomes and costs.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.